HER2+ BC: Recurrence risk remains even after achieving pCR with neoadjuvant pertuzumab+trastuzumabApril 5, 2021Breast Cancer
Risk of 5-year local recurrence declines with event-free years in newly diagnosed breast cancerApril 5, 2021Breast Cancer
Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinomaApril 5, 2021Breast Cancer
Advanced breast cancer: Palbociclib+ET associated with low burden of cutaneous toxicitiesApril 5, 2021Breast Cancer
Node-negative ER+/HER2− breast cancer: Adjuvant ET improves OS in older patients with comorbiditiesApril 5, 2021Breast Cancer
Pembrolizumab fails to improve OS in patients with previously treated metastatic TNBCApril 5, 2021Breast Cancer
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic riskApril 5, 2021Breast Cancer
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic riskApril 5, 2021Breast Cancer
